Your search for non small cell lung cancer returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Lea Eslava-Kim, PharmD remove
Drugs in the Pipeline remove

Your search for non small cell lung cancer returned 17 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

FDA to Review Ready-to-Dilute Pemetrexed Formulation

The FDA has accepted for review the New Drug Application (NDA) for Eagle's ready-to-dilute (RTD) Pemetrexed Injection 25mg/mL for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer and mesothelioma (in combination with cisplatin).
Drugs in the Pipeline

Anti-PDL1 Immunotherapy Demonstrates Efficacy in Phase 2 NSCLC Study

Genentech announced that the Phase 2 study of atezolizumab met its primary endpoint and shrank tumors in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1).
Drugs in the Pipeline

Biosimilar Candidate Comparable to Bevacizumab in NSCLC

Amgen and Allergan announced that their biosimilar candidate ABP 215 met its primary and secondary endpoints in a Phase 3 study evaluating its efficacy and safety compared with Avastin (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

FDA Designates Avelumab Orphan Drug for Skin Cancer

The FDA has granted Orphan Drug designation to the investigational cancer immunotherapy avelumab (Pfizer/Merck) for the treatment of Merkel cell carcinoma (MCC).
Drugs in the Pipeline

FDA Accepts Opdivo sBLA for Expanded Indication

The Food and Drug Administration (FDA) has accepted for filing and granted priority review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab, Bristol-Myers Squibb) for the treatment of previously treated patients with non-squamous (NSQ) non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

Alectinib NDA Accepted With Priority Review for NSCLC

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for alectinib (Genentech) for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Drugs in the Pipeline

Initial NDA for Investigational ALK Inhibitor Submitted to FDA

Ariad Pharmaceuticals announced the initiation of the first part of a rolling New Drug Application (NDA) submission to the Food and Drug Administration (FDA) for its investigational agent, brigatinib, for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant to crizotinib.